1. Introduction {#sec1}
===============

In Taiwan, head and neck cancer (HNC), which is diagnosed in more than 8,000 patients every year, is a leading cause of death \[[@B1], [@B2]\]. Clinical management of HNC includes surgery, radiation therapy (RT), and chemotherapy. Patients with early stage disease (stage I or II) are generally recommended single treatment modalities, such as surgery or RT, whereas treatment approaches utilizing combinations of several modalities are advised for patients with advanced stage disease (stage III or IV) \[[@B3]\].

RT is an important and effective treatment option in patients with HNC. However, radiation triggers an inflammatory response and precipitates damage to the vessel wall, eventually leading to the thickening of arterial walls, plaque formation, thrombosis, and altered blood flow or occlusion and stenosis of the artery. These disturbances in the vascular system are known to increase the risk of ischemic stroke and transient ischemic attack (TIA) \[[@B4]\]. Several studies have shown that RT in patients with HNC increased the risk of ischemic stroke and TIA \[[@B5]--[@B10]\].

Clinical trials that could robustly assess the efficacy of available treatment options in stroke prevention among patients with HNC treated with RT are limited, and the majority of the studies evaluated the efficacy of surgical management. Furthermore, no trial has thus far assessed pharmacological treatment options for primary or secondary stroke prevention. Oral antithrombotic therapy (OAT), including antiplatelet and anticoagulant agents, is frequently used in stroke prevention. However, the impact of OAT in patients with HNC treated with RT remains unclear \[[@B11]\].

The purpose of this study was to evaluate the efficacy and safety of OAT in patients with HNC treated with RT utilizing the National Health Insurance Research Database (NHIRD) of Taiwan and to provide a recommendation for general practitioners on the use of OAT in this patient population.

2. Methods {#sec2}
==========

2.1. Data Source {#sec2.1}
----------------

This population-based retrospective cohort study used the 1997--2009 NHIRD registry for patients with catastrophic diseases, published by the National Health Research Institutes of Taiwan. Taiwan launched a single-payer National Health Insurance program on March 1, 1995; as of 2014, 99.9% of Taiwan\'s population was enrolled. Foreign nationals in Taiwan are also eligible for this program. The database contains records of patients with catastrophic illnesses, ambulatory care expenditures by visits, inpatient expenditures by admissions, details of ambulatory care orders, and details of inpatient orders.

This study was approved by the institutional review board of Kaohsiung Medical University Hospital (KMUH-IRB-EXEMPT-20150009). Current NHIRD and hospital regulations and guidelines did not mandate informed consent in this retrospective cohort study. All procedures performed were in accordance with the ethical standards of the institutional research committee and the directives of the Declaration of Helsinki.

2.2. Study Population {#sec2.2}
---------------------

The first date that a patient was treated with RT was defined as the index date. We included all patients aged ≥ 20 years at the index date, with a diagnosis of HNC (ICD-9-CM code: 140 to 149) registered as catastrophic illness and received RT between 1998/1/1 and 2008/1/1. We excluded patients (1) who received RT before the index date, (2) who had other cancer diagnoses (ICD-9-CM code: 150 to 239) registered as catastrophic illness before the index date, (3) who had a diagnosis of ischemic stroke or TIA (ICD-9-CM code: 433--438) before the index date, (4) who took any OAT within 60 days before the index date, (5) who died within 30 days after the index date, and (6) whose first OAT prescriptions were prescribed due to an episode of ischemic stroke or TIA within 30 days after the index date among OAT users. The flowchart of the study population selection is presented in [Figure 1](#fig1){ref-type="fig"}.

2.3. Exposure {#sec2.3}
-------------

Patients who had at least one prescription of any class of OAT within 30 days after the index date were categorized into the user group. Nonusers were patients who did not take any OAT prescriptions within 30 days after the index date. OAT included aspirin (daily dose, 81--100 mg), clopidogrel, ticlopidine, dipyridamole, cilostazol, and warfarin.

2.4. Outcomes {#sec2.4}
-------------

Primary outcome of this study was ischemic stroke or TIA. The following definitions were used for ischemic stroke and TIA: emergency department visit or hospitalization due to ischemic stroke or TIA (ICD-9-CM code: 433--438) with examination by computed tomography (CT) or magnetic resonance imaging (MRI), revascularization procedures, or admission to intensive care unit (ICU). Secondary outcomes were death from any cause and major bleeding. Major bleeding included admission to the emergency department and hospitalization due to intracranial hemorrhage and gastrointestinal bleeding. ICD-9-CM codes of major bleeding are presented in the supplementary information (eTable 1) in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/6205158>.

2.5. Follow-Up {#sec2.5}
--------------

Two follow-up methods were performed in this study. For follow-up method I, all patients were followed from the index date to the day of the occurrence of the event ([Figure 2(a)](#fig2){ref-type="fig"}). To confirm that patients in the user group were compliant with OAT without discontinuation, follow-up method II was performed. Specifically, OAT nonusers were followed from the index date to the day of the occurrence of the event. Patients in the user group were first followed as OAT users from the index date to 60 days after the date of OAT discontinuation. Discontinuation was defined as failure to fill the subsequent prescription during the 60-day period. OAT users who discontinued OAT were then included in the nonuser group 60 days after the date of discontinuation and were followed as OAT nonusers ([Figure 2(b)](#fig2){ref-type="fig"}). Censoring was applied for patients who did not reach the outcomes of interest at the end of follow-up and those in the nonuser group who started to take an oral antithrombotic agent.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Descriptive statistics were performed to analyze baseline characteristics of the study population. Variables included age, gender, comorbidity (ICD-9-CM codes of comorbidity are presented in the supplementary information), and prescribed drugs. For continuous variables, data were presented as means and standard deviation (SD), and *t*-test was used to compare differences between users and nonusers. Categorical variables were presented as numbers and percentages, and the *χ* ^2^ test was used to compare differences between groups. The number of events, total follow-up person-years, and incidence of events (unit: events/1,000 person-years) were calculated. To assess the risk of events between users and nonusers, the Cox regression hazards model was used to calculate hazard ratios (HRs) and 95% confidence interval (CIs), and both univariate and multivariate analyses were performed. Covariates in multivariate analysis included age groups, gender, comorbidity, and prescribed drugs. In addition, 1-to-1 propensity score matching was performed to match users and nonusers \[[@B12]\]. Matched variables included age, gender, comorbidity, and prescribed drugs. For all statistical analyses performed in this study, *p* values \< 0.05 were defined as significant. All data processing and statistical analyses were performed using SAS® software, version 9.4 (SAS Institute Inc., Cary, NC).

3. Results {#sec3}
==========

In the present study, we identified 37,638 patients with HNC treated with RT within the defined time interval. Based on the definition of OAT exposure, there were 815 and 36,823 patients in the user and nonuser groups, respectively ([Figure 1](#fig1){ref-type="fig"}). The mean age of patients in the nonuser group (50.77 years) was significantly lower than that of patients in the user group (54.75 years, *p* \< 0.001). Additionally, the ratio of male patients was significantly higher in the user group than in the nonuser group (nonuser, 85.37%; user, 87.98%; *p* = 0.0367). Furthermore, the rates of hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, heart failure, atrial fibrillation, ischemic heart disease, peripheral vascular disease, and deep venous thrombosis were significantly higher in the user group than in the nonuser group. Only the rate of gastrointestinal ulcer (nonuser, 8.06%; user, 8.59%; *p* = 0.5836) was similar between the two groups. Finally, the percentage of patients taking prescribed drugs (ACEIs, ARBs, beta blockers, CCBs, NSAIDs, PPIs, and statin) was significantly higher in the user group than in the nonuser group ([Table 1](#tab1){ref-type="table"} and eTable 2). The incidences of ischemic stroke, TIA, death from any cause, and major bleeding were higher in the user group than in the nonuser group, as determined by both follow-up methods ([Table 2](#tab2){ref-type="table"} and eTable 3).

The Cox proportional hazards model was used to assess the association of OAT with ischemic stroke and TIA. Univariate analysis using follow-up method I revealed that OAT users were at a significantly higher risk for ischemic stroke or TIA, compared with nonusers (crude HR, 1.923; 95% CI, 1.244--2.972; *p* = 0.0032). However, there was no significant difference between these two groups by multivariate analysis (adjusted HR, 1.214; 95% CI, 0.776--1.898; *p* = 0.3961). By follow-up method II, there were no significant differences between the groups by both univariate (crude HR, 1.395; 95% CI, 0.345--5.646; *p* = 0.6403) and multivariate analyses (adjusted HR, 0.812; 95% CI, 0.199--3.309; *p* = 0.7712; [Table 3](#tab3){ref-type="table"}).

Multivariate analysis of ischemic stroke and TIA by follow-up method I also showed that older patients (age ≥ 45 years) were at a significantly higher risk of stroke and TIA than the reference population (age \< 45 years). Additionally, the risk of stroke and TIA was significantly lower in females by multivariate analysis using follow-up method I. Among all comorbidity variables included in the multivariate analysis by follow-up method I, hypertension (adjusted HR, 1.483; *p* = 0.0002), diabetes mellitus (adjusted HR, 1.654; *p* \< 0.0001), atrial fibrillation (adjusted HR, 2.467; *p* = 0.0026), and deep venous thrombosis (adjusted HR, 3.599; *p* = 0.0274) significantly increased the risk. Among the prescribed drugs evaluated in this study, ACEIs (adjusted HR, 1.697; *p* = 0.0350) and ARBs (adjusted HR, 1.983; *p* = 0.0305) were associated with significantly higher risk of ischemic stroke and TIA. Multivariate analysis by follow-up method II demonstrated similar results except for risk associated with ACEI and ARB use, which were not statistically significant ([Table 4](#tab4){ref-type="table"}).

Univariate analysis by follow-up method I also revealed that OAT users were at a significantly higher risk of death from any cause than were nonusers (crude HR: 1.493; 95% CI: 1.085--2.053; *p* = 0.0138). In contrast, there was no significant difference in the risk of death between the two groups by multivariate analysis (adjusted HR, 1.306; 95% CI, 0.945--1.806; *p* = 0.1062). Using follow-up method II, both univariate and multivariate analyses determined that the risk of death was higher in OAT users than in nonusers (crude HR, 1.915; 95% CI, 1.228--2.988; *p* = 0.0042 versus adjusted HR, 1.662; 95% CI, 1.059--2.607; *p* = 0.0271). However, univariate and multivariate analyses by follow-up methods I and II revealed that the risk of major bleeding was not significantly different between users and nonusers ([Table 3](#tab3){ref-type="table"}).

The total number of patients in the nonuser group was 36,823 in the present study. After 1-to-1 propensity score matching, there were 815 patients each in the nonuser and user groups. As shown in [Table 1](#tab1){ref-type="table"}, all baseline characteristics, age, gender, comorbidity, and prescribed drugs were well-matched and evenly distributed between the user and nonuser groups, and no significant differences in any of the variables were observed between users and nonusers ([Table 1](#tab1){ref-type="table"}).

The incidences of ischemic stroke, TIA, and death were higher in users than in nonusers as determined by follow-up method I; in contrast, the incidence of major bleeding was lower in the user group than in the nonuser group. Conversely, analysis performed by follow-up method II showed that while the incidences of ischemic stroke and TIA were higher in users than in nonuser group, the incidence of death and major bleeding was higher in users than in nonusers ([Table 2](#tab2){ref-type="table"}). Using the Cox proportional hazards model with follow-up method I, both univariate (crude HR, 1.727; 95% CI, 0.849--3.512; *p* = 0.1313) and multivariate analyses (adjusted HR, 1.609; 95% CI, 0.779--3.325; *p* = 0.1988) showed no significantly increased risk of ischemic stroke and TIA. This risk was not significantly different when the same analysis was performed by follow-up method II. Finally, no significant differences in the risk for death from any cause or major bleeding were found between users and nonusers by univariate or multivariate analyses using the Cox proportional hazards model and follow-up methods I and II ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

In this population-based cohort study to examine the efficacy and safety of OAT in patients with HNC treated with RT, we found that OAT did not significantly reduce the risk of the primary outcome of this study, that is, ischemic stroke and TIA. Among the secondary outcomes evaluated in the present study, OAT use was associated with increased mortality, although it did not significantly increase the risk of major bleeding.

The mean age of patients included in the present study ranged from 50 to 54 years, which was similar to that reported for patients with HNC by the annual Taiwan cancer registry report in 2012 (50--60 years) \[[@B2]\]. Additionally, the distribution of patient age in our study was similar to that reported by Huang et al. \[[@B7]\]; the highest percentage of patients was in the 45--54 age group. The percentage of male patients in our study (nonusers, 85%; users, 88%), albeit slightly lower than that observed in HNC patients in Taiwan cancer registry annual report (approximately 90%) \[[@B2]\], was similar to that observed in a study by Chu et al. (85%) \[[@B5]\]. Furthermore, while the ratio of nonuser patients with hypertension (nonusers, 15.27%) was similar to that reported by Chu and colleagues (16.1%), their cohort included more diabetic patients (13.1%) than the present study (nonusers, 9.23%) \[[@B5]\]. However, baseline characteristics of patients in the study by Huang et al. showed that the percentages of patients with hypertension (5.2%), diabetes (5.2%), and hyperlipidemia (0.4%) were distinctively lower than those in our study \[[@B7]\]. These differences were likely due to the differences in databases and definitions of comorbidities between the two studies. In the present study, the mean age of users was higher than nonusers, and the percentage of patients older than 65 years of age was higher in the user group. Furthermore, more OAT users suffered from cardiovascular diseases and were prescribed related drugs.

In the present study, the incidence rate of ischemic stroke and TIA was 5.57/1,000 person-years in the nonuser group and 10.32/1,000 person-years in the nonuser group by analysis using follow-up method I, which was lower than that reported by Chu et al. (between 11.5 and 11.8/1,000 person-years) \[[@B5]\]. One potential reason for this difference is the strict definition used for events in our study. Specifically, episodes of ischemic stroke or TIA were not only determined by the diagnostic ICD-9-CM codes but also determined by the codes for relevant imaging studies, revascularization procedures, and ICU admission. This approach enabled the precise detection of events. The Cox proportional hazards model applied with two follow-up methods and adjustment for all variables did not show any statistically significant differences between users and nonusers. Using this approach, stroke-related risk factors as variables such as age, gender, hypertension, diabetes mellitus, atrial fibrillation, and deep venous thrombosis showed a significantly increased risk of ischemic stroke and TIA \[[@B13]\]. Other variables, namely, ACEI and ARB use, were associated with a significantly increased risk of ischemic stroke and TIA, which might reflect the number of patients treated with ACEI or ARB for hypertension \[[@B14]\]. We also performed 1-to-1 propensity score matching to correct the imbalance in baseline characteristics between users and nonusers and no significantly difference was found by analysis with follow-up methods I and II.

No studies to date have evaluated the efficacy of OAT for primary prevention of ischemic stroke or TIA in patients with HNC undergoing RT \[[@B11]\]. Our findings demonstrated that OAT did not significantly reduce the risk of stroke and TIA in patients with HNC treated with RT, which might be due to antiplatelet resistance and low levels of international normalized ratio (INR) in patients taking oral vitamin K antagonists. Extensive focal inflammation and necrosis of vasa vasorum and adventitium were previously shown in patients treated with RT \[[@B11]\]. Chronic inflammation can cause antiplatelet resistance with accelerated platelet turnover \[[@B15]\]. In addition, an*in vivo* study revealed that low-dose aspirin did not have a significant effect on inhibition of platelet aggregation in irradiated mice \[[@B16]\]. Warfarin, an oral vitamin K antagonist, is usually used for stroke prevention in patients with atrial fibrillation and mechanical valve replacement. Guidelines suggest that INR levels should be between 2.0 and 3.0 for atrial fibrillation patients and between 2.5 and 3.5 for patients with mechanical valve replacement \[[@B13], [@B17]\]. Despite the lack of population-based studies on INR levels in Taiwanese patients, two hospital-based studies \[[@B18], [@B19]\] in Taiwan indicated that most patients on warfarin had INR levels of less than 2.0 (71.2% and 70% by Kuo et al. \[[@B18]\] and Yu et al. \[[@B19]\], resp.), which were below the recommended values.

To our knowledge, this is the first study to evaluate the efficacy of OAT in patients with HNC treated with RT. This cohort study utilized a large population size and longitudinal claims data. Additionally, our database included registry data for patients with catastrophic illness that allowed for precise identification of HNC cases. However, several limitations in our study need to be addressed. First, our study database did not contain information related to personal lifestyle choices such as smoking and alcohol consumption that are known risk factors for ischemic stroke \[[@B13]\]. Second, detailed information on physical examination, laboratory tests, imaging studies, clinical cancer stage, and TOAST etiologies of the stroke patients were not available in the database. For example, body weight, blood pressure, and low-density lipoprotein cholesterol levels are also associated with risk of ischemic stroke \[[@B13]\]. Imaging studies also provide additional information on the severity of carotid artery stenosis, and cancer staging can inform on mortality rates. Third, our database did not provide information on the doses used in each RT session. A study by Haynes et al. failed to demonstrate an effect of radiation dose on the risk of stroke in patients with HNC; radiation doses in stroke patients evaluated in that study ranged from 59.4 to 76.8 Gy \[[@B20]\]. Thus, although we could not include radiation dose as a variable in the regression models, its potential effect on the risk of ischemic stroke might be minimal. Fourth, not all ICD-9-CM codes included in our study outcomes were validated in the NHIRD. For ischemic stroke or TIA, the accuracy of the NHIRD in recording ischemic stroke diagnoses with the ICD-9-CM codes of 433.xx and 434.xx was high (94%) \[[@B21]\]. In contrast, we used the ICD-9-CM codes of 433.xx to 438.xx in the present study. While 435.xx to 438.xx were not yet validated, we confirmed the ischemic stroke and TIA events not only by these diagnosis codes but also by the procedure codes for imaging studies, revascularization procedures, and ICU admission. Fifth, we did not add each kind of statin use into our Cox regression models due to small sample size. The confidence intervals of each kind of statin were too wide to be presented.

5. Conclusions {#sec5}
==============

In conclusion, OAT did not significantly reduce the risk of ischemic stroke or TIA in patients with HNC treated with RT. Furthermore, no significant major bleeding was observed in patients taking OAT. Furthermore, randomized clinical trials are needed to comprehensively evaluate the efficacy and safety of OAT in this study population.
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###### 

Baseline characteristics of head and neck cancer patients with radiation therapy and study population after propensity score matching.

  Variables                      Study population   Study population after PSM                                                                   
  ------------------------------ ------------------ ---------------------------- ------- -------- ---------- ------- --------- ------- --------- --------
  *Age (years)*                                                                                                                                   
   \<45                          11561              31.40                        172     21.10    \<0.0001   173     21.23     172     21.10     0.9989
   45 to 54                      12835              34.86                        259     31.78               257     31.53     259     31.78      
   55 to 64                      7341               19.94                        208     25.52               210     25.77     208     25.52      
   65 to 74                      3789               10.29                        126     15.46               123     15.09     126     15.46      
   ≥75                           1297               3.52                         50      6.14                52      6.38      50      6.14       
   Mean ± SD                     50.77              ±11.79                       54.75   ±11.84   \<0.0001   54.51    ±12.12   54.75    ±11.84   0.6823
  *Gender*                                                                                                                                        
   Men                           31434              85.37                        717     87.98    0.0367     722     88.59     717     87.98     0.7002
   Women                         5389               14.63                        98      12.02               93      11.41     98      12.02      
  *Comorbidity*                                                                                                                                   
   Hypertension                  5623               15.27                        248     30.43    \<0.0001   257     31.53     248     30.43     0.6298
   Diabetes mellitus             3399               9.23                         178     21.84    \<0.0001   183     22.45     178     21.84     0.7655
   Dyslipidemia                  1828               4.96                         72      8.83     \<0.0001   64      7.85      72      8.83      0.4737
   Chronic kidney disease        279                0.76                         23      2.82     \<0.0001   23      2.82      23      2.82      1.0000
   Heart failure                 314                0.85                         38      4.66     \<0.0001   34      4.17      38      4.66      0.6297
   Atrial fibrillation           162                0.44                         16      1.96     \<0.0001   13      1.60      16      1.96      0.5740
   Gastrointestinal ulcer        2968               8.06                         70      8.59     0.5836     76      9.33      70      8.59      0.6028
   Ischemic heart disease        1233               3.35                         139     17.06    \<0.0001   137     16.81     139     17.06     0.8949
   Peripheral vascular disease   87                 0.24                         8       0.98     \<0.0001   6       0.74      8       0.98      0.5914
   Deep venous thrombosis        41                 0.11                         11      1.35     \<0.0001   9       1.10      11      1.35      0.6527
  *Prescribed drug*                                                                                                                               
   ACEI                          550                1.49                         55      6.75     \<0.0001   51      6.26      55      6.75      0.6878
   ARB                           274                0.74                         30      3.68     \<0.0001   37      4.54      30      3.68      0.3825
   Beta blocker                  118                0.32                         8       0.98     0.0012     8       0.98      8       0.98      1.0000
   CCB                           51                 0.14                         13      1.60     \<0.0001   15      1.84      13      1.60      0.7030
   NSAIDs                        13898              37.74                        402     49.33    \<0.0001   415     50.92     402     49.33     0.5196
   PPI                           1335               3.63                         82      10.06    \<0.0001   83      10.18     82      10.06     0.9346
   Statin                        84                 0.23                         13      1.60     \<0.0001   10      1.23      13      1.60      0.5287

PSM, propensity score matching; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.

###### 

Incidence of study outcomes in head and neck cancer patients with radiation therapy between oral antithrombotic therapy users and nonusers.

  Follow-up method                                                                                 Outcome                  Nonuser     User                                   
  ------------------------------------------------------------------------------------------------ ------------------------ ----------- ----------- ------ --------- --------- -------
  Study population: nonuser (*n* = 36,823); user (*n* = 815)                                                                                                                   
  Method I                                                                                         Ischemic stroke or TIA   600         107648.01   5.57   21        2034.16   10.32
  Death                                                                                            1220                     108714.85   11.22       39     2087.92   18.68     
  Major bleeding                                                                                   1730                     106366.72   16.26       43     2037.69   21.10     
  Method II                                                                                        Ischemic stroke or TIA   613         109023.26   5.62   2         318.45    6.28
  Death                                                                                            1237                     110096.69   11.24       20     318.62    62.77     
  Major bleeding                                                                                   1762                     107720.68   16.36       14     314.46    44.52     
                                                                                                                                                                               
  Study population after 1-to-1 propensity score matching: nonuser (*n* = 815); user (*n* = 815)                                                                               
  Method I                                                                                         Ischemic stroke or TIA   12          1995.20     6.01   21        2034.16   10.32
  Death                                                                                            26                       2007.16     12.95       39     2087.92   18.68     
  Major bleeding                                                                                   46                       1928.04     23.86       43     2037.69   21.10     
  Method II                                                                                        Ischemic stroke or TIA   25          3370.45     7.42   2         318.45    6.28
  Death                                                                                            43                       3389.00     12.69       20     318.62    62.77     
  Major bleeding                                                                                   78                       3281.99     23.77       14     314.46    44.52     

TIA, transient ischemic attack.

^†^Unit of incidence rate: 1,000 person-years.

###### 

Association of study outcomes in head and neck cancer patients with radiation therapy between oral antithrombotic therapy users and nonusers.

  Follow-up method                                          Outcome                  Crude HR   95% CI   *p* value   Adjusted HR^†^   95% CI   *p* value            
  --------------------------------------------------------- ------------------------ ---------- -------- ----------- ---------------- -------- ----------- -------- --------
  Study population                                                                                                                                                  
  Method I                                                  Ischemic stroke or TIA   1.923      1.244    2.972       0.0032           1.214    0.776       1.898    0.3961
  Death                                                     1.493                    1.085      2.053    0.0138      1.306            0.945    1.806       0.1062   
  Major bleeding                                            1.237                    0.914      1.675    0.1678      0.951            0.699    1.294       0.7490   
  Method II                                                 Ischemic stroke or TIA   1.395      0.345    5.646       0.6403           0.812    0.199       3.309    0.7712
  Death                                                     1.915                    1.228      2.988    0.0042      1.662            1.059    2.607       0.0271   
  Major bleeding                                            1.391                    0.819      2.363    0.2215      1.057            0.620    1.802       0.8397   
                                                                                                                                                                    
  Study population after 1-to-1 propensity score matching                                                                                                           
  Method I                                                  Ischemic stroke or TIA   1.727      0.849    3.512       0.1313           1.609    0.779       3.325    0.1988
  Death                                                     1.442                    0.878      2.369    0.1484      1.511            0.916    2.493       0.1061   
  Major bleeding                                            0.888                    0.586      1.346    0.5758      0.875            0.575    1.330       0.5313   
  Method II                                                 Ischemic stroke or TIA   0.666      0.142    3.130       0.6068           0.506    0.110       2.330    0.3816
  Death                                                     1.458                    0.833      2.550    0.1865      1.450            0.822    2.556       0.1995   
  Major bleeding                                            0.951                    0.512      1.768    0.8748      0.853            0.460    1.583       0.6149   

HR, hazard ratio; CI, confidence interval; TIA, transient ischemic attack.

^†^Adjusted variables included age, gender, comorbidity, and prescribed drugs.

###### 

Cox proportional hazard model of ischemic stroke and transient ischemic attack in head and neck cancer patients with radiation therapy between oral antithrombotic therapy users and nonusers.

  Variables                       Follow-up method I    Follow-up method II                                                                
  ------------------------------ --------------------- ---------------------- ---------------- ---------- ------- ------- ---------------- ----------
  *User versus nonuser*          1.214                 0.776                  1.898            0.3961     0.812   0.199   3.309            0.7712
  *Age (years)*                                                                                                                             
   \<45                          1.000                 ---                    ---              ---        1.000   ---     ---              ---
   45 to 54                      2.509                 1.954                  3.221            \<0.0001   2.503   1.949   3.214            \<0.0001
   55 to 64                      3.561                 2.742                  4.625            \<0.0001   3.567   2.746   4.634            \<0.0001
   65 to 74                      4.498                 3.357                  6.028            \<0.0001   4.403   3.279   5.912            \<0.0001
   ≥75                           5.722                 3.794                  8.631            \<0.0001   5.615   3.707   8.505            \<0.0001
  *Gender*                                                                                                                                  
   Men                           1.000                 ---                    ---              ---        1.000   ---     ---              ---
   Women                         0.708                 0.567                  0.884            0.0023     0.708   0.567   0.885            0.0024
  *Comorbidity*                                                                                                                             
   Hypertension                  1.483                 1.209                  1.819            0.0002     1.492   1.215   1.832            0.0001
   Diabetes mellitus             1.654                 1.310                  2.088            \<0.0001   1.652   1.305   2.091            \<0.0001
   Dyslipidemia                  0.821                 0.588                  1.145            0.2445     0.838   0.600   1.170            0.3000
   Chronic kidney disease        1.146                 0.508                  2.583            0.7427     1.188   0.526   2.679            0.6788
   Heart failure                 0.993                 0.485                  2.032            0.9847     1.057   0.517   2.162            0.8799
   Atrial fibrillation           2.467                 1.369                  4.444            0.0026     2.521   1.398   4.547            0.0021
   Gastrointestinal ulcer        0.920                 0.691                  1.224            0.5659     0.926   0.696   1.233            0.5993
   Ischemic heart disease        1.213                 0.873                  1.686            0.2500     1.224   0.877   1.710            0.2352
   Peripheral vascular disease   0.924                 0.229                  3.723            0.9118     0.956   0.237   3.852            0.9496
   Deep vein thrombosis          3.599                 1.154                  11.225           0.0274     3.761   1.206   11.724           0.0224
  *Prescribed drugs*                                                                                                                        
   ACEI                          1.697                 1.038                  2.775            0.0350     1.549   0.922   2.602            0.0981
   ARB                           1.983                 1.066                  3.688            0.0305     1.874   0.982   3.578            0.0568
   Beta blocker                  1.592                 0.588                  4.313            0.3603     1.631   0.602   4.420            0.3360
   CCB                           0.000                 0.000                  3.62 × 10^144^   0.9530     0.000   0.000   2.63 × 10^160^   0.9580
   NSAIDs                        0.929                 0.781                  1.105            0.4043     0.939   0.789   1.117            0.4773
   PPI                           0.772                 0.431                  1.381            0.3833     0.797   0.445   1.426            0.4447
   Statin                        1.225                 0.296                  5.066            0.7791     1.438   0.349   5.935            0.6153

HR, hazard ratio; CI, confidence interval; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.

^†^Adjusted variables included age, gender, comorbidity, and prescribed drugs.

[^1]: Academic Editor: Gelin Xu
